0000899243-21-011496.txt : 20210315
0000899243-21-011496.hdr.sgml : 20210315
20210315091519
ACCESSION NUMBER: 0000899243-21-011496
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210315
FILED AS OF DATE: 20210315
DATE AS OF CHANGE: 20210315
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jacques Rachelle Suzanne
CENTRAL INDEX KEY: 0001772610
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39067
FILM NUMBER: 21740026
MAIL ADDRESS:
STREET 1: C/O CORBUS PHARMACEUTICALS HOLDINGS, INC
STREET 2: 100 RIVER RIDGE DRIVE
CITY: NORWOOD
STATE: MA
ZIP: 02062
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viela Bio, Inc.
CENTRAL INDEX KEY: 0001734517
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 MEDIMMUNE WAY
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
BUSINESS PHONE: 240-558-0038
MAIL ADDRESS:
STREET 1: 1 MEDIMMUNE WAY
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-15
1
0001734517
Viela Bio, Inc.
VIE
0001772610
Jacques Rachelle Suzanne
C/O VIELA BIO, INC.,
ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO
GAITHERSBURG
MD
20878
1
0
0
0
Stock Option (right to buy)
48.96
2021-03-15
4
D
0
14716
D
2030-06-18
Common Stock
14716
0
D
Stock Option (right to buy)
48.96
2021-03-15
4
D
0
7358
D
2030-06-18
Common Stock
7358
0
D
Reflects disposition of options to purchase Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the "Merger Agreement"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. ("Purchaser"), and for certain purposes, Horizon Therapeutics plc, including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding options that was held by a non-employee director of the Issuer, subject solely to the continued services of the holder of such option with the Issuer through such date, was accelerated and became fully vested, and each of such outstanding options was canceled and converted into the right to receive a cash amount (without interest) equal to the product of (i) the number of shares subject to such option, multiplied by (ii) the excess of (x) $53.00 over (y) the exercise price payable per share under such option.
/s/ Nishant Dharia, Attorney-in-fact
2021-03-15